The findings suggest that LMI 1195 yields a comparable estimate of cardiac sympathetic innervation as C11 HED. LMI 1195 retention index (r=0.89, p<0.0001) and defect score (r-0.99, p<0.0001) correlated highly with HED. LV-to-lung ratios were comparable between the two tracers. In addition, LMI 1195 seems to offer more favorable kinetics for early cardiac imaging than HED. A significant difference in blood clearance was observed between the two tracers resulting in a LV-to-blood ratio of LMI-1195 higher than HED within the first five minutes following administration (p<0.05).

“We believe LMI 1195 may represent a first-in-class agent and useful diagnostic tool for a significant population of patients at risk for sudden cardiac death,” said Cesare Orlandi, M.D., Chief Medical Officer of Lantheus Medical Imaging. “Nuclear imaging provides a unique tool to measure the molecular changes in the heart, including cardiac function of the norepinephrine transporter (NET), in a non-invasive and repeatable manner. Lantheus developed LMI 1195 to target the NET and we are encouraged by these initial results that have been obtained in a variety of clinical conditions. Data from this and other collaborations with academic centers in Canada and Europe have allowed us to progress the LMI 1195 program to this stage and have provided the basis for the initiation of a Phase 3 trial in ischemic cardiomyopathy patients scheduled to receive an ICD. We look forward to initiating this pivotal study later in the year.”


About LMI 1195
LMI 1195, developed by Lantheus, is an internally discovered small molecule that may be a first-in-class fluorine-18-based PET radiopharmaceutical imaging agent designed to assess cardiac sympathetic nerve function. LMI 1195 has the potential to become a useful tool in the diagnostic assessment of ischemic heart failure patients who may be at risk of sudden cardiac death.

Heart failure is associated with changes in the cardiac sympathetic nerve function. These changes appear early in the development of heart failure. The cardiac neuronal norepinephrine transporter (NET) has been shown to be a useful target for the non-invasive monitoring of the cardiac sympathetic status and the assessment of the likelihood of a heart failure patient to develop fatal arrhythmias. Nuclear cardiac imaging provides a unique tool to measure the molecular changes in the heart, including cardiac function of NET, in a non-invasive and repeatable manner. Lantheus developed LMI 1195 to target the NET and are encouraged by initial results that have been obtained in a variety of conditions.

Molecular Imaging Homepage